Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium Journal Article

   

Authors:	Tefferi, A.; Abdel-Wahab, O.; Ervantes, F. C.; Crispino, J. D.; Finazzi, G.; Girodon, F.; Gisslinger, H.; Gotlib, J.; Kiladjian, J. J.; Levine, R. L.; Licht, J. D.; Mullally, A.; Odenike, O.; Pardanani, A.; Silver, R. T.; Solary, E.; Mughal, T.
Article Title:	Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium
Abstract:	Immediately following the 2010 annual American Society of Hematology (ASH) meeting, the 5th International Post-ASH Symposium on Chronic Myelogenous Leukemia and BCRABL1-Negative Myeloproliferative Neoplasms (MPNs) took place on 7-8 December 2010 in Orlando, Florida, USA. During this meeting, the most recent advances in laboratory research and clinical practice, including those that were presented at the 2010 ASH meeting, were discussed among recognized authorities in the field. The current paper summarizes the proceedings of this meeting in BCR-ABL1-negative MPN. We provide a detailed overview of new mutations with putative epigenetic effects (TET oncogene family member 2 (TET2), additional sex comb-like 1 (ASXL1), isocitrate dehydrogenase (IDH) and enhancer of zeste homolog 2 (EZH2)) and an update on treatment with Janus kinase (JAK) inhibitors, pomalidomide, everolimus, interferon-a, midostaurin and cladribine. In addition, the new 'Dynamic International Prognostic Scoring System (DIPSS)-plus' prognostic model for primary myelofibrosis (PMF) and the clinical relevance of distinguishing essential thrombocythemia from prefibrotic PMF are discussed. © 2011 Macmillan Publishers Limited All rights reserved.
Keywords:	cancer survival; myelofibrosis; unclassified drug; gene mutation; busulfan; hydroxyurea; fatigue; myeloid metaplasia; neutropenia; ascites; diarrhea; drug withdrawal; side effect; conference paper; alpha interferon; low drug dose; multiple cycle treatment; anemia; leukopenia; nausea; neuropathy; thrombocytopenia; vomiting; peripheral neuropathy; protein; weight reduction; abdominal pain; coughing; dizziness; pruritus; drug induced headache; hypotension; polycythemia; epigenetics; thrombosis; splenomegaly; scoring system; thrombocyte count; pleura effusion; liver function test; triacylglycerol lipase blood level; leukocytosis; everolimus; lymphadenopathy; hypertriglyceridemia; myeloproliferative neoplasm; thrombocytosis; polycythemia vera; thrombocythemia; opportunistic infection; cladribine; isocitrate dehydrogenase; mastocytosis; myeloproliferative; mouth ulcer; phase 2 clinical trial (topic); phase 1 clinical trial (topic); midostaurin; phlebotomy; pomalidomide; cancer prognosis; psychopathy; urticaria pigmentosa; momelotinib; ruxolitinib; additional sex comb like1 protein; enhancer of zeste homolog 2 protein; pipobroman; tet oncogene family member 2 protein
Journal Title:	Blood Cancer Journal
Volume:	1
Issue:	3
ISSN:	2044-5385
Publisher:	Nature Publishing Group
Date Published:	2011-03-04
Start Page:	e7
Language:	English
PROVIDER:	scopus
PMCID:	PMC3255279
PUBMED:	23471017
DOI:	10.1038/bcj.2011.4
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-84859306234&partnerID=40&md5=fd3d7b28811af437a54ed810d8b34752
Notes:	--- - Cited By (since 1996):1 - "Export Date: 7 May 2013" - ":doi 10.1038/bcj.2011.4" - ": Chemicals/CASbusulfan, 55-98-1; cladribine, 4291-63-8; everolimus, 159351-69-6; hydroxyurea, 127-07-1; isocitrate dehydrogenase, 9001-58-5; midostaurin, 120685-11-2; momelotinib, 1056634-68-4; pipobroman, 54-91-1; pomalidomide, 19171-19-8, 443912-23-0, 443919-33-3; protein, 67254-75-5; ruxolitinib, 1092939-17-7, 941678-49-5" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/40774